沙库巴曲缬沙坦钠在血液透析合并慢性心衰患者中的临床疗效研究  

Clinical Efficacy of Sacubitril Valsartan Sodium in Hemodialysis Patients Complicated with Chronic Heart Failure

作　　者：李细女 敖辉平 康文龄 蒋芳 刘桃英 LI Xinü;AO Huiping;KANG Wenling;JIANG Fang;LIU Taoying(Nephrology Department,Xinyu People's Hospital,Xinyu 338000,China)

机构地区：[1]新余市人民医院肾病内科,江西新余338000 [2]新余市人民医院心电图室,江西新余338000

出　　处：《中国医学创新》2025年第7期19-23,共5页Medical Innovation of China

基　　金：新余市科技计划项目(2033090808)。

摘　　要：目的:评估沙库巴曲缬沙坦钠用于血液透析合并慢性心力衰竭(CHF)患者中的临床疗效。方法:选择2022年10月—2023年10月新余市人民医院收治的103例血液透析合并CHF患者,根据随机数字表法分为观察组(n=55)、对照组(n=48),两组均实施常规治疗,对照组加以缬沙坦治疗,观察组加以沙库巴曲缬沙坦钠治疗。比较两组治疗前、治疗6个月后的心功能指标、肾功能指标、炎症因子水平及用药安全性。结果:治疗前,两组心功能指标、肾功能指标、炎症因子水平比较,差异均无统计学意义(P>0.05)。治疗6个月后,观察组左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)均低于对照组,左室射血分数(LVEF)高于对照组,差异均有统计学意义(P<0.05);治疗6个月后,观察组血尿素氮(BUN)、血肌酐(Scr)水平均低于对照组,差异均有统计学意义(P<0.05);治疗6个月后,观察组C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平均低于对照组,差异均有统计学意义(P<0.05)。两组不良反应、不良心血管事件发生率比较,差异均无统计学意义(P>0.05)。结论:将沙库巴曲缬沙坦钠用于血液透析合并CHF患者中具有积极效果,有利于改善患者心、肾功能,促进炎症症状的缓解,从而提高疗效,并具有较高的安全性。Objective:To evaluate the clinical efficacy of Sacubitril Valsartan Sodium in hemodialysis patients with chronic heart failure(CHF).Method:A total of 103 hemodialysis patients with CHF treated in Xinyu People's Hospital from October 2022 to October 2023 were selected and divided into observation group(n=55)and control group(n=48)according to random number table method.Both groups received conventional treatment,the control group received Valsartan treatment,and the observation group received Sacubitril Valsartan Sodium treatment.Cardiac function index,renal function index,inflammatory factor level and drug safety between the two groups before treatment and 6 months after treatment were compared.Result:Before treatment,there were no significant differences in cardiac function indexes,renal function indexes and inflammatory factors between the two groups(P>0.05).After 6 months of treatment,left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)in observation group were lower than those in control group,and left ventricular ejection fraction(LVEF)was higher than that in control group,the differences were statistically significant(P<0.05).After 6 months of treatment,the levels of blood urea nitrogen(BUN)and serum creatinine(Scr)in observation group were lower than those in control group,the differences were statistically significant(P<0.05).After 6 months of treatment,the levels of C reactive protein(CRP),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)in observation group were lower than those in control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions and adverse cardiovascular events between the two groups(P>0.05).Conclusion:The application of Sacubitril Valsartan Sodium in hemodialysis patients with CHF has positive effects,which is conducive to improving the cardiac and renal function of patients,promoting the alleviation of inflammatory symptoms,thus improving the efficacy and h

关 键 词：沙库巴曲缬沙坦钠 血液透析 慢性心力衰竭 心功能 肾功能 

分 类 号：R541.6[医药卫生—心血管疾病] R692.5[医药卫生—内科学]